T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor-stimulated macrophages by Walk, Ryan et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Surgery Faculty Publications Surgery
11-2012
T-cell activation is enhanced by targeting IL-10
cytokine production in toll-like receptor-stimulated
macrophages
Ryan Walk
Steven Elliott
Felix C. Blanco
Jason A. Snyder
Ashley M. Jacobi
See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_surgery_facpubs
Part of the Cell and Developmental Biology Commons, Immunology and Infectious Disease
Commons, and the Surgery Commons
This Journal Article is brought to you for free and open access by the Surgery at Health Sciences Research Commons. It has been accepted for inclusion
in Surgery Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact
hsrc@gwu.edu.
APA Citation
Walk, R., Elliott, S., Blanco, F. C., Snyder, J. A., Jacobi, A. M., Rose, S., Behlke, M., Salem, A., Vukmanovic, S., & Sandler, A. D. (2012).
T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor-stimulated macrophages. Immunotargets and
Therapy, 1 (). http://dx.doi.org/10.2147/ITT.S32615
Authors
Ryan Walk, Steven Elliott, Felix C. Blanco, Jason A. Snyder, Ashley M. Jacobi, Scott Rose, Mark Behlke,
Aliasger Salem, Stanislav Vukmanovic, and Anthony D. Sandler
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_surgery_facpubs/407
© 2012 Walk et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
ImmunoTargets and Therapy 2012:1 13–23
ImmunoTargets and Therapy
T-cell activation is enhanced by targeting IL-10  
cytokine production in toll-like receptor-  
stimulated macrophages
Ryan M Walk1,2
Steven T Elliott2
Felix C Blanco2
Jason A Snyder2
Ashley M Jacobi3
Scott D Rose3
Mark A Behlke3
Aliasger K Salem4
Stanislav Vukmanovic2
Anthony D Sandler2
1Department of Surgery, Walter Reed 
Army Medical Center, Washington, 
DC, USA; 2Sheikh Zayed Institute 
for Pediatric Surgical Innovation, 
Children’s National Medical Center, 
Washington, DC, USA; 3Integrated 
DNA Technologies, Coralville, IA, 
USA; 4Division of Pharmaceutics, 
University of Iowa, Iowa City, IA, USA
Correspondence: Stanislav Vukmanovic 
Sheikh Zayed Institute for Pediatric 
Surgical Innovation, Children’s National 
Medical Center, 111 Michigan Avenue, 
Washington DC, 20010, USA 
Tel +1 202 476 3078 
Fax +1 202 476 1260 
Email svukmano@cnmc.org
Abstract: Toll-like receptor (TLR) agonists represent potentially useful cancer vaccine adju-
vants in their ability to stimulate antigen-presenting cells (APCs) and subsequently amplify 
the cytotoxic T-cell response. The purpose of this study was to characterize APC responses to 
TLR activation and to determine the subsequent effect on lymphocyte activation. We exposed 
murine primary bone marrow-derived macrophages to increasing concentrations of agonists to 
TLRs 2, 3, 4, and 9. This resulted in a dose-dependent increase in production of not only tumor 
necrosis factor–alpha (TNF-α), a surrogate marker of the proinflammatory response, but also 
interleukin 10 (IL-10), a well-described inhibitory cytokine. Importantly, IL-10 secretion was not 
induced by low concentrations of TLR agonists that readily produced TNF-α. We subsequently 
stimulated lymphocytes with anti-CD3 antibody in the presence of media from macrophages 
activated with higher doses of TLR agonists and observed suppression of interferon gamma 
release. Use of both IL-10 knockout macrophages and IL-10 small-interfering RNA (siRNA) 
ablated this suppressive effect. Finally, IL-10 siRNA was successfully used to suppress CpG-
induced IL-10 production in vivo. We conclude that TLR-mediated APC stimulation can induce 
a paradoxical inhibitory effect on T-cell activation mediated by IL-10.
Keywords: toll-like receptors, innate immunity, IL-10
Introduction
Immunotherapy remains an exciting, yet largely unfulfilled, modality in the treatment 
of malignant disease. Myriad treatment strategies have been explored, including vac-
cination against viral precursors, cytokine manipulation, adoptive T-cell transfer, and 
dendritic cell administration.1 Obvious theoretical potential and astonishing anecdotal 
successes continue to fuel investigation.
The development of tumor-specific vaccines for either adjuvant or neoadjuvant 
therapy represents an extremely attractive approach; however, the challenges associated 
with their development have been starkly illustrated as the intricacies of the so-called 
“escape” phase of cancer immunoediting have been elucidated. These include loss 
of antigen-presenting machinery, decreased expression of tumor antigens, reduced 
sensitivity to immune effector molecules, expression of inhibitory molecules, and 
induction of regulatory cells including regulatory T-cells (Tregs).1
Stimulation of Toll-like receptors (TLRs), components of the innate immune sys-
tem, are extensively studied as a means for overcoming tumor escape mechanisms. 
TLRs are the best-characterized class of pattern recognition receptors in mammalian 
species,2 detecting unique nonself-molecular patterns conserved throughout entire 
classes of pathogens.3 The reasoning behind their use as anticancer agents is twofold. 
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First, activation of the innate immune system and subsequent 
production of an appropriate cytokine and chemokine milieu 
will promote a direct cytotoxic antitumor response.4 Second, 
their activation also augments the development of adaptive 
responses that can be exploited to accelerate vaccines for 
tumor-specific immunity.5
There are likely between 10–15 unique TLRs in 
mammalian species.2 At least 11 TLRs are identified in 
humans, and these are well conserved in mouse species.6 
TLRs recognize multiple pathogen-associated molecular 
patterns, including bacterial lipoproteins (TLR2); double-
stranded RNA (TLR3); lipopolysaccharide (LPS) (TLR4); 
flagellin (TLR5); single-stranded viral RNA (TLR7); and 
unmethylated CpG DNA (TLR9), that are unique to bacteria 
and viruses.
In order to augment the development of a cancer vaccine, 
our laboratory has explored the use of TLR agonists as vac-
cine adjuvants. In so doing, we sought to examine the murine 
APC cytokine response to TLR activation and the subsequent 
effect of this activation on lymphocytes. Here, we identify a 
dose-response curve of cytokine production in bone marrow-
derived macrophages (BMM) after the activation of TLRs 
2, 3, 4, and 9. This cytokine production is characterized by 
increasing levels of not only the proinflammatory cytokine 
tumor necrosis factor–alpha (TNF-α), but also the inhibitory 
cytokine interleukin 10 (IL-10) that inhibited lymphocyte 
activation in vitro. Finally, we show that this inhibitory effect 
can be overcome by targeting IL-10 with small-interfering 
RNA (siRNA) both in vitro and in vivo.
Materials and methods
Mice
Female A/J, C57BL/6, and IL-10 deficient (C57BL/6 back-
ground) mice were purchased at 4 weeks of age from The 
Jackson Laboratory (Bar Harbor, ME). After arrival, mice 
were acclimated for at least 4 days prior to use. Animals 
were housed in specific pathogen-free conditions in the 
Animal Laboratory at Children’s National Medical Center. 
All mice were handled in accordance with the guidelines of 
the Institutional Animal Care and Use Committee.
Reagents
OK-432 was obtained from Chugai Pharmaceutical Co 
(Tokyo, Japan). CpG-ODN 1826 was purchased from Coley 
Pharmaceutical Group (Wellesley, MA; Lot# C44-0604-
AE1A). Polyinosinic:polycytidylic acid sodium salt (Poly 
I:C) was purchased from Sigma-Aldrich (St Louis, MO; 
Product #PO913).
Macrophage harvest and growth
Primary bone marrow macrophages were directly harvested 
from sacrificed A/J and C57BL/6 mice. Femurs and tibias 
were dissected and the intramedullary canals were flushed 
with PD solution (phosphate-buffered saline containing 1% 
penicillin–streptomycin) via a 26 g needle until the bones 
were clear. Cells were resuspended in PD solution and 
centrifuged. The cells were then cultured in canted neck flasks 
(CellStar 658190 T75 Flask, Greiner Bio-One, Monroe, NC; 
suspension culture, sterile, plug seal cap, 250 mL) containing 
30% L929 cell-conditioned media in a humidified incubator 
at 37°C with 5% CO
2
. Cells were refed on either day 2 or 3, 
then plated between days 6 and 9 into 24-well plates. 2 × 105 
cells were plated in each well with 350 µL of D10 solution 
(Dulbecco’s modified Eagle’s medium [DMEM], supple-
mented with 10% fetal bovine serum [FBS], penicillin [100 
IU/mL], streptomycin [100 µg/mL] [all Sigma-Aldrich], 
and 1% L-glutamine [Mediatech Inc, Manassas, VA]). The 
24-well plates were then returned to the incubator and mac-
rophages were given at least 16 hours to acclimate prior to 
stimulation. The obtained cell population was 99.6% positive 
for CD11b, 88.7% for F4/80, 83.9% for CD14, 30.2% for 
CD11c, and ,1% for Gr1 (data not shown).
Flow cytometry
Cultured bone marrow cells were collected and stained with 
the following fluorochrome-conjugated murine antibod-
ies (mAbs) obtained from eBioscience (San Diego, CA): 
phycoerythrin:cyanine-5 (PE-Cy5)-conjugated CD11b 
(M1/70), allophycocyanin (APC)-conjugated CD11c (N418), 
phycoerythrin (PE)-conjugated F4/80 (BM8), fluorescein 
isothiocyanate (FITC)-conjugated CD14 (Sa2-8), and 
allophycocyanin (APC)-conjugated Gr1 (RB6-8C5). Flow 
cytometry was performed using FACS Calibur (BDBiosci-
ence, San Jose, CA); results were analyzed using FlowJo 
software (Treestar, Ashland, OR).
Macrophage stimulation
At the conclusion of the acclimation period, varying amounts of 
CpG, Poly I:C, and OK-432 were administered to the cells. The 
macrophages were then reincubated for 24 hours before either 
cytokine assay or splenocyte stimulation was performed.
Splenocyte harvest
Spleens of sacrificed A/J and C57BL/6 mice were removed 
and crushed through cell strainers (BD Biosciences, San Jose, 
CA). Strained cells were then centrifuged and re-suspended in 
R10 Solution (RPMI media containing 10% FBS, penicillin 
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[100 IU/mL], streptomycin [100 µg/mL], 1% L-glutamine, 
25 nM HEPES buffer [Mediatech Inc], and 0.005 mM 
B-mercaptoethanol [Sigma-Aldrich]). A cell-count was 
performed using trypan blue to ensure cell viability. 2 × 105 
cells per well were plated into 96-well round-bottom plates; 
each well contained 150 µL of RPMI solution.
Splenocyte stimulation
Immediately after the splenocytes were plated, 150 µL of 
stimulated macrophage supernatant was added to each well in 
combination with 1.0 µg/mL of purified anti-CD3 (BD Bio-
sciences; Cat # 553058, αCD3e) for lymphocyte activation. 
Splenocytes were then incubated at 37°C for 48 hours prior 
to cytokine assay.
siRNA oligonucleotide design  
and validation
All RNA oligonucleotides used in this study were synthesized 
and high-pressure liquid chromatography (HPLC)-purified by 
Integrated DNA Technologies (Coralville, IA). Compound 
identity was verified by electrospray ionization mass spec-
trometry (ESI-MS) and compound purity was measured to 
be better than 90% by analytical HPLC. Final duplexes were 
prepared in sodium salt form. Ten Dicer-substrate siRNAs 
(DsiRNAs)7,8 targeting murine IL-10 (NM_010548) were 
tested for functional potency as described below. The most 
potent DsiRNA (mIL10-1) was an asymmetric duplex with 
a 25-base passenger strand and a 27-base guide strand with 
sequence 5′-pGGAUCUUAGCUACGGAAACAACtc-3′ 
(S-strand) and 5′-pGAGUUGUUUCCGUUAGCUAAGAU
CCCU-3′, where RNA bases are uppercase, DNA bases are 
lowercase, and p is phosphate. For all experiments, the nega-
tive control DsiRNA NC1 was employed with sequence 5′-p
CGUUAAUCGCGUAUAAUACGCGUat-3′ (S-strand) and 
5’-pAUACGCGUAUUAUACGCGAUUAACGAC-3’ (AS-
strand) and for some experiments the positive control anti-
HPRT1 (NM_000194) DsiRNA was employed with sequence 
5′-pGCCAGACUUUGUUGGAUUUGAAAtt-3′ (S-strand) 
and pAAUUUCAAAUCCAACAAAGUCUGGCUU (AS-
strand). The anti-HPRT1 DsiRNA works as a positive control 
for human, mouse, and rat cells lines equally well.
The murine macrophage cell line RAW 264.7 was 
employed for all DsiRNA validation experiments (ATCC, 
Manassas, VA; Cat #TIB-71). Cells were split into 48-well 
plates at 60% confluency (250,000 cells per well) at the 
time of transfection in 250 µL DMEM containing 10% FBS 
(ATCC). RNA duplexes were transfected at 10 nM, 1 nM, 
and 0.1 nM final concentrations with 2.5 µL TransIT-TKO® 
(Mirus, Madison, WI) per 50 µL OptiMEM™ I (Invitrogen, 
Carlsbad, CA). The HPRT1 DsiRNA was used as an internal 
positive control to assess transfection efficiency and the NC1 
DsiRNA was a nontargeting negative control. All transfections 
were performed in triplicate. Twenty-four hours post-trans-
fection, all transfected wells were stimulated with 50 ng/mL 
Escherichia coli K12 LPS (InvivoGen, San Diego, California) 
for 8 hours to induce IL-10 production. RNA was harvested 
32 hours post-transfection using the SV96 Total RNA Isolation 
Kit (Promega, Madison, WI) and cDNA was synthesized using 
150 ng total RNA with SuperScript™-II Reverse Transcriptase 
(Invitrogen) per the manufacturer’s instructions using both 
random hexamer and oligo-dT priming.
Quantitative real-time polymerase chain reaction (PCR) 
was performed using 10 ng cDNA per 10 µL reaction, Immo-
lase™ DNA Polymerase (Bioline, Randolph, MA), 200 nM 
primers, and 200 nM probe. IL-10 specific primers were 
IL-10-For 5′-GTACAGCCGGGAAGACAATAAC, IL-10-
Rev 5′-TTGGCAACCCAAGTAACCC, and probe IL-10-P 
5′ FAM-TGCCTTCAGCCAGGTGAAGACTTT-IBFQ 
(Iowa Black FQ, dark quencher). HPRT1-specific primers 
were HPRT-For 5′-GACTTTGCTTTCCTTGGTCAGGCA, 
HPRT-Rev 5′-GGCTTATATCCAACACTTCGTGGG 
and probe HPRT-P 5 ′-MAXN-ATGGTCAAGGT 
CGCAAGCTTGCTGGT-IBFQ. Cycling conditions 
employed were: 95°C for 10 minutes followed by 40 cycles of 
two-step PCR with 95°C for 15 seconds and 60°C for 1 minute. 
PCR and fluorescence measurements were done using an ABI 
Prism™ 7900 Sequence Detector (Applied Biosystems Inc, 
Foster City, CA). All reactions were performed in triplicate. 
Expression data were normalized to levels of an internal 
control gene, RPL23 (NM_022891). RPL23 specific prim-
ers were RPL23-For 5′ CTGTGAAGGGAATCAAGGGA, 
RPL23-Rev 5′ TGTCGAATTACCACTGCTGG, and 
probe RPL23-P 5′ FAM-CTGAACAGACTTCCTGCTGC 
TGGTG-IBFQ. Copy number standards were run in parallel 
using linearized cloned amplicons for qualitative PCR assays. 
Unknowns were extrapolated against standards to establish 
absolute  quantitative measurements.
siRNA transfection
Primary bone marrow macrophages were harvested as described 
above. Cells were plated into 24-well plates and allowed to 
acclimate for 16–24 hours. Lipofectamine 2000 (Invitrogen) 
was combined with siRNA as directed by the manufacturer’s 
guidelines. The final concentration of siRNA added to the cells 
was 33 nM. Cells were incubated in serum-free transfection 
medium for 8 hours, at which time the supernatants were 
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removed and replaced with growth media. The cells were 
stimulated after 16–24 hours of reacclimation.
To test targeting of cytokine response in vivo, we targeted 
IL-10 by delivering IL-10 siRNA loaded into poly(lactic-co-
glycolic acid) (PLGA) microparticles (MPs) (Division of 
Pharmaceutics, University of Iowa, Iowa City IA). Nonspe-
cific siRNA (DsiRNA NC1) and empty PLGA MPs were used 
as controls. A/J mice (four per group) received intraperitoneal 
administration of siRNA in PLGA MPs (2.5 µg per mouse 
suspended in 100 µL of phosphate-buffered solution). No 
signs of distress were observed in any of the groups.
Peritoneal exudates were collected at 6, 12, and 18 hours 
after PLGA injection. Peritoneal exudates were centrifuged 
and cell pellets suspended and cultured overnight at 37°C in 
DMEM with 10% serum (D10). After incubation, the superna-
tant was discarded and adherent cells were placed in triplicate 
in 24-well plates with 250 µL of D10 media and allowed to 
attach for 6 hours. Cells were then stimulated with 1 µg/mL 
CpG. After 12 hours of stimulation, supernatants were recov-
ered and analyzed by enzyme-linked immunosorbent assay 
(ELISA) for their IL-10 and TNF-α concentrations.
Enzyme-linked immunosorbent assay
Cell culture supernatants were collected from triplicate wells 
after stimulation. TNF-α and IL-10 secreted by BMM and 
peritoneal macrophages, and interferon-gamma (IFN-γ) 
secreted by lymphocytes were measured by ELISA using 
purified capture and biotinylated detection antibody pairs (BD 
Biosciences). The ELISA plates were read using the Multiskan 
FC microplate photometer (Thermo Scientific, Hudson, NH) 
at 450 nm. The data was analyzed using SkanIT software 
(Thermo Fisher Scientific, Vantaa, Finland).
Statistical analysis
Experiments were performed in triplicates. Error bars indicate 
standard error of the mean (SEM). Results are representative of 
three independent experiments. For reverse transcription-PCR 
experiments, error bars represent SEM for the triplicate quan-
titative PCR reactions performed on three biological replicates. 
The statistical significance was evaluated using Student’s t-test.
Results
TLR agonists stimulate bone marrow 
macrophages in a dose-dependent fashion
To characterize the responses to TLR stimulation, primary 
BMM were exposed to varying concentrations of specific 
TLR compounds and IL-12, TNF-α and IL-10 responses were 
measured. We anticipated identifying an optimal TLR agonist 
and dosage; however, irrespective of the TLR agonist used, the 
BMM response was characterized by increasing production and 
eventual plateau of the cytokine measured. In all TLRs tested, 
production of IL-10 characteristically lagged behind that of 
TNF-α (Figure 1) or IL-12 (data not shown) and only emerged 
at higher concentrations of TLR-agonist. This indicates that 
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Figure 1 Macrophage TNF-α and IL-10 production after exposure to varying concentrations of TLR agonists. Primary bone marrow macrophages were harvested from A/J mice, 
plated, and stimulated with Poly I:C, a TLR3 agonist (A), Cpg, a TLR9 agonist (B), OK 432, a TLR2/4 agonist (C), or various combinations of two agonists, as indicated. Cytokine levels 
were measured by ELISA 16–24 hours after stimulation and expressed as pg/mL (A–C) or TNF-α/IL-10 ratios (D, mean and standard deviation of three separate experiments).
Notes: The differences between untreated and treated cultures are statistically significant (**P , 0.01; ***P , 0.001).
Abbreviations: TLR, Toll like receptor; TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; ELISA, Enzyme linked Immunosorbent Assay; Poly I:C, Polyinosinic:polycytidylic 
acid; Cpg, Cytosine-phosphate-guanin.
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an optimal proinflammatory dose of each TLR-agonist can 
be identified to maximize the production of TNF-α prior to 
induction of IL-10 secretion. Importantly, secretion of IL-10 
reaches maximal values at the same or slightly higher TLR 
agonist concentrations relative to those that induce maximal 
TNF-α production. Furthermore, no combination of two TLR 
agonists was capable of selectively stimulating proinflamma-
tory responses, as evident from the ratios of TNF-α and IL-10 
production (Figure 1D). These observations suggest that in vivo 
TLR agonist administration may be impractical if the goal is to 
obtain a predominantly proinflammatory response.
Macrophage IL-10 production inhibits  
in vitro lymphocyte activation
Given significant IL-10 production at higher doses of TLR 
agonists, we hypothesized that a paradoxical anti-inflammatory 
response to TLR agonist could occur. Therefore, we devel-
oped an in vitro model to investigate the effect on lymphocyte 
activation. Primary murine BMM were first exposed to TLR 
agonists. After exposure, the activated macrophage supernatant 
was collected and transferred to a culture of autologous murine 
splenocytes stimulated with anti-CD3 antibody. Lymphocyte 
activation was determined by IFN-γ production. Remarkably, 
exposure of autologous splenocytes to the cytokine milieu of 
TLR-activated macrophages consistently led to lymphocyte 
suppression in comparison with controls exposed to anti-CD3 
antibody alone (Figure 2A). Profound suppression of T cell 
activation was achieved even with supernatants with cultures 
containing relatively lower levels of IL-10 (eg, supernatants 
from OK-432-stimulated macrophages). Importantly, IFN-γ 
production was induced only by anti-CD3, and not by any agent 
transferred from the primary culture (Figure 2B).
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Figure 2 Modulation of anti-CD3-induced IFN-γ production by TLR-stimulated macrophage supernatants. Whole A/J (A) or C57BL/6 (B) spleen cells were plated in the 
presence of 1.0 µg/mL of anti-CD3 antibody. 
Notes: The activation was performed in the presence of 100% supernatants of macrophages stimulated with OK-432 (10 µg/mL), Cpg (3 µg/mL), LPS (10 µg/mL), or Poly I:C 
(50 µg/mL), as indicated. Concentrations of combination of OK-432 and Poly I:C were also 10 µg/mL and 50 µg/mL, respectively. Not applicable (NA) represents splenocytes 
plated with anti-CD3 antibody alone in the absence of any macrophage supernatant. Cytokine levels were measured by ELISA 48 hours after stimulation. The differences 
between cultures containing supernatants from untreated and treated macrophages are statistically significant (***P , 0.001).
Abbreviations: TLR, Toll like receptor; TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; ELISA, Enzyme linked Immunosorbent Assay; Poly I:C, Polyinosinic:polycytidylic 
acid; Cpg, Cytosine-phosphate-guanin; LPS, Lipopolysaccharide; IFN, Interferon.
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To evaluate the role of IL-10 in this suppressive lympho-
cyte response, the experiment was repeated using BMM from 
IL-10-knockout mice. Supernatants from TLR stimulated 
IL-10 KO BMM did not inhibit IFN-γ production from 
autologous splenocytes stimulated with anti-CD3 antibody 
(Figure 3). These observations suggest that IL-10 is a critical 
cytokine inhibiting lymphocyte activation in this model.
IL-10 siRNA targeting in macrophages 
reversed the suppression of lymphocyte 
activation induced by TLR-stimulated 
macrophage supernatants
To directly and selectively target IL-10 production, we 
investigated the use of IL-10 siRNA to suppress macrophage 
IL-10 production. siRNA constructs were designed and sub-
sequently tested for their ability to suppress IL-10 secretion 
from a RAW macrophage cell line by quantitative reverse 
transcription-PCR. IL-10 mRNA knockdown by the most 
effective construct is shown in Figure 4. Lipofectamine 2000 
was used to transfect BMM with this IL-10 siRNA construct. 
Subsequent CpG-mediated activation of transfected BMM led 
to a notable decrease in secreted levels of IL-10 (Figure 5A) 
with minimal effect on TNF-α production (Figure 5B).
After demonstrating that BMM IL-10 production could be 
constrained through the administration of IL-10 siRNA, we 
applied this finding to the in vitro model of macrophage- mediated 
lymphocyte activation described above.  Supernatant from the 
siRNA lipofected and stimulated macrophages was exposed 
to autologous splenocytes in the presence of R10 media and 
anti-CD3 antibody. Subsequent lymphocyte activation was 
measured via IFN-γ ELISA. As seen in  Figure 5C, lympho-
cytes exposed to IL-10 siRNA lipofected macrophage super-
natant demonstrated an approximately fourfold increase in 
IFN-γ activity. These findings show that suppression of IL-10 
following macrophage TLR stimulation induces a cytokine 
milieu conducive to T-cell activation.
IL-10 production is suppressed in vivo 
following treatment with IL-10 siRNA-
loaded PLgA microparticles
PLGA MPs loaded with IL-10 or control siRNA were 
injected intraperitoneally at a dose of 2.5 µg per mouse and 
peritoneal exudate was harvested 6 hours later. This time 
point was chosen because after 6 hours of in vitro exposure, 
more than 90% of peritoneal exudate cells engulfed PLGA 
MPs (Figure 6) and longer incubations were associated with 
concomitant nonspecific effects (data not shown). CpG 
stimulation (1 µg/mL) of peritoneal exudate cells resulted in 
significantly reduced IL-10 levels following treatment with 
IL-10 siRNA-loaded PLGA-MPs, while TNF-α levels were 
not affected (Figure 7A). Furthermore, IFN-γ response fol-
lowing T lymphocyte activation was higher when stimulated 
in the presence of supernatants of in vivo IL-10 siRNA-
loaded macrophages (Figure 7B).
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Figure 3 Modulation of anti-CD3-induced IFN-γ production by supernatants of TLR-stimulated IL-10-deficient macrophages. 
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Discussion
Our findings demonstrate the paradoxical anti-inflammatory 
response of murine BMM to TLR stimulation. This effect is 
mediated by IL-10 production, a well-described suppressor of 
immune responses. IL-10’s suppressive effects are mediated 
through a variety of mechanisms; including downregulation 
of macrophage and dendritic cell antigen-presenting capacity, 
blocking secretion of cytokines and chemokines, preventing 
expression of costimulatory molecules and chemokine recep-
tors, increasing generation of free-radicals and upregulating 
expression of β2-integrin ligand (intracellular adhesion 
molecule 1).9 In addition, the current work shows that IL-10 
produced by macrophage stimulation is responsible for sup-
pressing T-cell activation. In direct contrast, the production of 
proinflammatory cytokines, such as TNF-α drive the polar-
ization of CD4+ T-cells towards a Th-1 phenotype. Thus, the 
pro- vs anti-inflammatory cytokine balance is crucial in the 
control of immune homeostasis,10 and their relative expres-
sion in response to TLR stimulation has implications for 
the clinical application of TLR agonists to cancer treatment, 
including their use as cancer vaccine adjuvants.
Recent evidence supports the concept of a paradoxical 
anti-inflammatory response to TLR stimulation. Murine bone 
marrow dendritic cells stimulated with TLR 2 (Pam3CSK4) 
and TLR 4 (LPS) agonists demonstrate a dose-dependent 
increase in IL-10 secretion.10 Moreover, high-dose CpG 
induces CD19+ dendritic cell-mediated activation of sup-
pressor T-cells via an indoleamine 2,3-dioxygenase (IDO) 
pathway, a response that is particularly prominent in areas 
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Figure 4 Validation of anti-IL-10 DsiRNA. NC1, hPRT, and mIL10-1 DsiRNAs 
were transfected into RAW264.7 cells at 10 nM, 1 nM, and 0.1 nM concentrations. 
Notes: At 24 hours, cells were stimulated with 50 ng/mL LPS and RNA was 
harvested 8 hours later. RT-qPCR was performed and relative expression of the 
hPRT mRNA (in the hPRT DsiRNA transfected cultures) and IL-10 mRNA (in the 
IL-10-1 DsiRNA transfected cultures) normalized to the RPL23 are shown, setting 
the control NC1 transfection to 100%. The differences between NC1- and hPRT- or 
IL-10-specific siRNA are statistically significant (**P , 0.01; ***P , 0.001).
Abbreviations: IL-10, Interleukin 10; hPRT, hypoxantine-guanine phosphorybosyl-
transferase; RT-qPCR, Reverse transcriptase quantitative polymerase chain reaction.
of chronic inflammation and resultant constitutive IDO 
expression, such as the tumor microenviornment.11,12 Taken 
together, these findings highlight the variability of the immu-
nologic response to TLR agonists, ostensibly as mechanisms 
to allow the avoidance of unregulated local inflammation. 
Unfortunately, they add additional layers of intricacy to the 
use of TLR agonists as vaccine adjuvants. Our finding that the 
transition from pro- to anti-inflammatory cytokine secretion 
occurs following relatively small increases of TLR agonist 
concentration additionally complicates their use. Beyond 
optimizing the target microenvironment for TLR agonist 
administration, simple variation in individual pharmacokinet-
ics could make accurate adjuvant dosing challenging.
Dendritic cells are the most important antigen presenting 
cell type in promoting immune responses.13,14 Just like mac-
rophages, dendritic cells produce IL-10 in response to TLR 
stimulation.10 In fact, inhibition of IL-10 production by dendritic 
cells is one of the many strategies being attempted with the 
hope of successful immunotherapy of tumors.15 However, IL-10 
is produced by and affects the function of many cell types,16 
and the ultimate fate of immune response induction does not 
rest solely on dendritic cells. In fact, the immunosuppressive 
potential of macrophages and myeloid-derived suppressor 
cells is well known.17 Hence, targeting of IL-10 production 
as part of raising anti-tumor immunity should be inclusive 
of as many cell types as possible. Our siRNA approach is 
designed to efficiently target cells with antigen-processing 
abilities, which includes both dendritic cells and macrophages.
By constraining macrophage TLR-mediated IL-10 pro-
duction through administration of siRNA and, consequently, 
augmenting activated splenocyte IFN-γ production, we have 
demonstrated an ability to augment the efficacy of TLR-
agonists in vitro. In order for this finding to have clinical 
utility, in vivo IL-10 modulation will be necessary. Several 
potential strategies exist in which investigators have explored 
the use of anti-IL-10 antibodies; one in particular has dem-
onstrated its efficacy in humans in the treatment of systemic 
lupus erythematosus.18 The “paradoxically beneficial” effect 
of anti-IL-10 is due to an effect of IL-10 on B cells helping 
produce (auto)antibodies in lupus. The use of IL-10 signaling 
pathway inhibitors are also shown to have in vitro efficacy, as 
demonstrated in the above-mentioned study by Hirata et al, 
where inhibitors of the p38 mitogen-activated protein kinase 
(MAPK), and c-jun N-terminal kinase (JNK)1/2 pathways 
effectively constrained IL-10 production.10 Finally, a recent 
study utilized JC virus-like particles for the targeted deliv-
ery of IL-10 siRNA in mice.19 While the first of these three 
options has been the most extensively studied, the last two 
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Figure 5 IL-10 siRNA decreases IL-10 production and abolishes suppression in vitro. A/J macrophages were transfected with IL-10 siRNA using Lipofectamine 2000 reagent 
and stimulated with 1.0 µg/mL Cpg. Shown are levels of IL-10 (A), or TNF-α and IL-10 in primary overnight cultures (B), or levels of anti-CD3-induced IFN-γ production 
by spleen cells in the presence of primary culture supernatants (C). 
Notes: The differences between Lipofectamine 2000-treated and IL-10 siRNA-treated cultures are statistically significant for IL-10, but not TNF-α production (*P , 0.05; 
***P , 0.001).
Abbreviations: TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; Cpg, Cytosine-phosphate-guanin; IFN, Interferon; hPRT, hypoxantine-guanine phosphorybosyltransferase.
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may prove to be more effective, as TNF-α and IL-10 secre-
tion can exhibit a synergistic relationship in which the 
presence of the former amplifies secretion of the latter.20 As 
demonstrated by our data, the converse does not seem to be 
true; moreover, previous studies on human monocytes have 
demonstrated that IL-10 can in fact inhibit TNF-α secretion.21 
De novo prevention of IL-10 production is therefore less 
likely to prevent TNF-α secretion than post hoc ablation of 
its effects.
Previous studies have both detected secretion of anti-
inflammatory cytokines and demonstrated techniques to 
constrain their production. However, our study takes com-
parable findings a step further by developing an in-vitro 
model to demonstrate their effects on T-cell activation. 
The fact that TLR 9 in humans is expressed in B-cells 
and plasmacytoid dendritic cells,22 but not monocytes or 
macrophages like in the mouse, appears to limit the impact 
of our findings to the mouse. However, our findings were 
not specific to TLR9 stimulation, but pertained to all TLR 
receptors tested.
Additionally, we demonstrated that siRNA constructs 
can be effectively delivered by PLGA MPs both in vitro and 
in vivo. The clinical use of PLGA MPs as a drug-delivery 
system is expanding as it is a biocompatible polymer with-
out systemic toxicity.23 We demonstrated that the uptake 
of PLGA MPs by peritoneal macrophages reached at least 
90% at 6 hours and that the uptake continued beyond that 
time point as indicated by the rising number of MPs per cell 
(Figure 6). This load was not deleterious as no suppression 
of cytokine production was observed after a 12- and 24-hour 
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Figure 6 Uptake of PLgA MPs in vivo. A/J mice were injected with PLgA MPs and peritoneal exudate cells were examined at indicated time intervals (1, 2, 6 and 12 hours 
post injection) by light microscopy. Shown are representative images for each time point (A), percentage of cells loaded with PLgA MPs (B) and average number of PLgA 
MPs per cell (C).
Abbreviation: PLgA MPs, Poly lactic-co-glycolic acid microparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
21
Toll-like receptor activation of macrophages
ImmunoTargets and Therapy 2012:1
exposure to empty MPs (data not shown). Slow biodegradable 
materials such as PLGA could improve the stability of siRNA 
and promote a sustained and localized effect on the target 
organ or tissue.24 Macrophages preferentially phagocytose 
the MPs, thus making these PLGA polymers a useful vehicle 
for targeting macrophage function. Our in vivo experiments 
indicated that macrophage exposure to siRNA-loaded PLGA 
MPs was effective in suppressing IL-10 production, an effect 
that could potentially be used in vaccine formulations to 
augment host immunity.
In conclusion, our data demonstrates that the secre-
tion of proinflammatory cytokines in response to TLR 
 activation is balanced by the anti-inflammatory effects of 
IL-10 secretion in a dose-dependent fashion. The production 
of IL-10  prevents the development of the cytotoxic T-cell 
response in an in vitro model of TLR activation. Targeting 
macrophage IL-10 production through the administration of 
siRNA abolishes the suppressive T-cell effect. As this applies 
to the development of cancer vaccines, strategies to either 
constrain or ablate IL-10 and enhance the proinflammatory 
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Figure 7 Inhibition of IL-10 production in vivo by siRNA. A/J mice were injected with empty, IL-10 siRNA-loaded, or control NC siRNA-loaded PLgA MPs. Peritoneal 
exudate cells were isolated, stimulated with Cpg and examined for production of TNF-α and IL-10 (A). Supernatants of these cultures were added to anti-CD3-stimulated 
spleen cells and production of IFN-γ was assessed (B). 
Note: The differences between empty PLGA-treated and IL-10 siRNA-treated cells are statistically significant (***P , 0.001).
Abbreviations: IL-10, Interleukin 10; Cpg, Cytosine-phosphate-guanin; PLgA, MPs-Poly lactic-co-glycolic acid microparticles; IFN, Interferon.
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response may improve the efficacy of TLR agonists as  vaccine 
adjuvants. Finally, in vivo suppression of macrophage IL-10 
was successfully accomplished by IL-10 siRNA-loaded 
PLGA-MP. MPs loaded with siRNA appear to present a 
potential method for targeting of IL-10 production. These 
findings should have important implications for modulating 
immunity with siRNA strategies.
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